To introduce and evaluate the Essilor Stellest 2.0 lens designed to enhance myopia control in pediatric patients.
Key Findings:
Stellest 2.0 demonstrated a significant reduction in axial elongation, with eye growth approximately 1.88 times slower than the original lens.
Younger children, particularly those aged 8.5 years or younger, may benefit more from the updated lens design.
Interpretation:
The design changes in Stellest 2.0 aim to amplify the optical signal to slow myopia progression, addressing a growing public health concern.
Limitations:
Further research is needed to confirm long-term outcomes of the Stellest 2.0 lens.
Challenges remain in educating families about the role of spectacles in myopia management beyond vision correction.
Conclusion:
The Stellest 2.0 lens represents a significant advancement in non-invasive myopia control strategies for children, contributing to the broader efforts in managing childhood myopia.
More than 300 professionals gathered for three days of innovation, education, and collaboration, highlighting the latest advances in ophthalmic technology and clinical practice